SEQENS
Allan Jensen has over two decades of experience in the chemical industry, currently serving as the Commercial Manager at SEQENS since December 2018, following the company's rebranding after Novacap SAS acquired Chemoxy International Ltd. Prior to this role, Allan worked at Dow Chemical from April 2004 to December 2011 as the Commercial Development Manager, overseeing solvent recovery activities and contributing to R&D initiatives. Allan began their career as an R&D Scientist at Chemoxy International (formerly Ascot plc) from November 1999 to April 2004.
This person is not in any offices
SEQENS
SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1.4 MM€ and operates 24 manufacturing plants and 10 R&D centers in Europe, North America and Asia. 3,400 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.